GW 441756

Pricing Availability   Qty
Cat.No. 2238 - GW 441756 | C17H13N3O | CAS No. 504433-23-2
Description: Potent, selective TrkA inhibitor
Chemical Name: 1,3-Dihydro-3-[(1-methyl-1H-indol-3-yl)methylene]-2H-pyrrolo[3,2-b]pyridin-2-one
Purity: ≥99% (HPLC)
Datasheet
Citations (4)
Reviews
Literature

Biological Activity

Potent, selective inhibitor of the NGF receptor tyrosine kinase A (TrkA) (IC50 = 2 nM). Displays > 100-fold selectivity over a range of other kinases.

Licensing Information

Sold for research purposes under agreement from GlaxoSmithKline.

Technical Data

M. Wt 275.31
Formula C17H13N3O
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 504433-23-2
PubChem ID 16219401
InChI Key NXNQLECPAXXYTR-UHFFFAOYSA-N
Smiles CN1C=C(C=C2C(=O)NC3=CC=CN=C23)C2=C1C=CC=C2

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 4.13 15

Preparing Stock Solutions

The following data is based on the product molecular weight 275.31. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.15 mM 24.22 mL 121.08 mL 242.15 mL
0.75 mM 4.84 mL 24.22 mL 48.43 mL
1.5 mM 2.42 mL 12.11 mL 24.22 mL
7.5 mM 0.48 mL 2.42 mL 4.84 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

References

References are publications that support the biological activity of the product.

Wood et al (2004) Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg.Med.Chem.Lett. 14 953 PMID: 15013000


If you know of a relevant reference for GW 441756, please let us know.

View Related Products by Product Action

View all Trk Receptor Inhibitors

Keywords: GW 441756, GW 441756 supplier, Potent, selective, TrkA, inhibitors, inhibits, Neurotrophin, Receptors, Receptor, Tyrosine, Kinases, RTKs, GW441756, GlaxoSmithKline, GSK, Trk, 2238, Tocris Bioscience

4 Citations for GW 441756

Citations are publications that use Tocris products. Selected citations for GW 441756 include:

Edwards et al (2011) Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion. J Natl Cancer Inst 103 1162 PMID: 21771732

Wang et al (2008) Cellular assays for high-throughput screening for modulators of Trk receptor tyrosine kinases. Curr Chem Genomics 1 27 PMID: 20161825

Rees et al (2016) Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Oncotarget 12 109 PMID: 26656090

Lawn et al (2015) Neurotrophin signaling via TrkB and TrkC receptors promotes the growth of brain tumor-initiating cells. Nat Chem Biol 290 3814 PMID: 25538243


Do you know of a great paper that uses GW 441756 from Tocris? Please let us know.

Reviews for GW 441756

There are currently no reviews for this product. Be the first to review GW 441756 and earn rewards!

Have you used GW 441756?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cancer

Cancer Research Product Guide

A collection of over 750 products for cancer research, the guide includes research tools for the study of:

  • Cancer Metabolism
  • Epigenetics in Cancer
  • Receptor Signaling
  • Cell Cycle and DNA Damage Repair
  • Angiogenesis
  • Invasion and Metastasis
Kinases

Kinases Product Listing

A collection of over 400 products for kinase research, the listing includes inhibitors of:

  • Receptor Tyrosine Kinases
  • Protein Kinases A, C, D and G
  • PI-3 Kinase, Akt and mTOR
  • MAPK Signaling
  • Receptor Serine/Threonine Kinases
Depression

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease

Huntington's Disease Poster

Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Pain

Pain Poster

Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.